<DOC>
	<DOCNO>NCT03030638</DOCNO>
	<brief_summary>This study aim characterise use single-agent olodaterol single-agent indacaterol , market LABAs authorise COPD , asthma , clinical practice .</brief_summary>
	<brief_title>Drug Utilization Study Olodaterol</brief_title>
	<detailed_description>Boehringer Ingelheim GmbH ( BI ) develop olodaterol , inhale long-acting beta2-agonist ( LABA ) , indication chronic obstructive pulmonary disease ( COPD ) . Because use LABAs associate increased morbidity mortality patient asthma , health authority request conduct post-approval drug utilisation study assess potential off-label use olodaterol asthma characterise use olodaterol clinical practice . The single agent indacaterol , market LABA authorise clinical practice COPD asthma , also assess . Study objectives include follow : ( 1 ) Quantify frequency off-label use olodaterol indacaterol among new user medication ; ( 2 ) Describe baseline characteristic new user olodaterol indacaterol . This cross-sectional study use information among new user olodaterol indacaterol collect follow healthcare database : PHARMO Database Network Netherlands , National Registers Denmark , IMS Health Information Solutions ( IMS ) Real-World Evidence ( RWE ) Longitudinal Patient Database ( LPD ) France . The source population patient enrol select study database date olodaterol become available database 's country . The study group patient source population receive first dispense single-agent formulation olodaterol primary objective indacaterol secondary objective least 12 month continuous enrolment study database . The study describe number proportion new user indication potential off-label use accord medical history use co-medications .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion : receive first prescription/dispensing singleagent formulation olodaterol indacaterol study period ( prescriptions/dispensings ever ) patient must least 12 consecutive month enrolment database index date Exclusion criterion : Individuals miss implausible value age sex exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>